BIAFW实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 04:00):
Our systems believe the stock currently is undervalued by 0.52% compare to its pairs and should correct upwards.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment...

Stats
今日成交量	1 000
平均成交量	0
市值	3.50M
EPS	$-0.200 ( Q1 \| 2024-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 39.71
ATR14	$0 (0.00%)

AWH 13.74%

BIAF 1.41%

BIAFW -52.29%

INBS 1.59%

LMDXW 0.00%

PRE -1.33%

PRENW -2.11%

Insider Trading

Date	Person	Action	Amount	type
2023-12-01	Platt Jamie	Buy	0
2023-09-18	Joyce Roby	Buy	0	Common Stock
2021-11-22	Joyce Roby	Buy	14 285	Warrant
2023-09-18	Reveles Xavier Trinidad	Sell	0	Common Stock
2021-08-26	Reveles Xavier Trinidad	Sell	2 142	Stock Option (Right to Buy)

INSIDER POWER
64.00
Last 96 transactions
Buy: 1 799 574 \| Sell: 997 504

相关性 (AI algo v.1.1b): Undervalued: 0.52% $0.302 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

bioAffinity Technologies, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

bioAffinity Technologies, 财务报表

Annual	2023
营收:	$2.53M
毛利润:	$542 023 (21.40 %)
EPS:	$-0.910

FY	2023
营收:	$2.53M
毛利润:	$542 023 (21.40 %)
EPS:	$-0.910

FY	2022
营收:	$4 803.00
毛利润:	$4 336.00 (90.28 %)
EPS:	$-1.810

Financial Reports:

No articles found.

bioAffinity Technologies, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

bioAffinity Technologies,

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.